

## **XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants**

Qian Wang<sup>1,#</sup>, Yicheng Guo<sup>1,#</sup>, Anthony Bowen<sup>1,2,#</sup>, Ian A. Mellis<sup>1,3,#</sup>,  
Riccardo Valdez<sup>4</sup>, Carmen Gherasim<sup>4</sup>, Aubree Gordon<sup>5,\*</sup>, Lihong Liu<sup>1,3,\*</sup>, David D. Ho<sup>1,3,6,\*</sup>

<sup>1</sup>Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA

<sup>2</sup>Division of Infectious Diseases, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA

<sup>3</sup>Department of Pathology and Cell Biology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA

<sup>4</sup>Department of Pathology, University of Michigan, Ann Arbor, MI, USA

<sup>5</sup>Department of Epidemiology, University of Michigan, Ann Arbor, MI, USA

<sup>6</sup>Department of Microbiology and Immunology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA

#These authors contributed equally

\*Correspondence: [gordonal@umich.edu](mailto:gordonal@umich.edu) (A.G.), [ll3411@cumc.columbia.edu](mailto:ll3411@cumc.columbia.edu) (L.L.),  
[dh2994@cumc.columbia.edu](mailto:dh2994@cumc.columbia.edu) (D.D.H.)

### **Abstract**

COVID-19 vaccines have recently been updated with the spike protein of SARS-CoV-2 XBB.1.5 subvariant alone, but their immunogenicity in humans has yet to be fully evaluated and reported, particularly against emergent viruses that are rapidly expanding. We now report that administration of an updated monovalent mRNA vaccine (XBB.1.5 MV) to uninfected individuals boosted serum virus-neutralization antibodies significantly against not only XBB.1.5 (27.0-fold) and the currently dominant EG.5.1 (27.6-fold) but also key emergent viruses like HV.1, HK.3, JD.1.1, and JN.1 (13.3-to-27.4-fold). In individuals previously infected by an Omicron subvariant, serum neutralizing titers were boosted to highest levels (1,764-to-22,978) against all viral variants tested. While immunological imprinting was still evident with the updated vaccines, it was not nearly as severe as the previously authorized bivalent BA.5 vaccine. Our findings strongly support the official recommendation to widely apply the updated COVID-19 vaccines to further protect the public.

**Key words:** COVID-19; SARS-CoV-2; Omicron subvariants; XBB.1.5 monovalent mRNA vaccine; HV.1; HK.3; JD.1.1; JN.1; immunological imprinting

## Introduction

Although the World Health Organization (WHO) has announced the conclusion of the emergency phase of the COVID-19 pandemic<sup>1</sup>, SARS-CoV-2 continues to spread and evolve<sup>2,3</sup>. Emerging viral variants increasingly evade host immunity acquired through vaccination, natural infection, or both, thereby posing a persistent threat to public health<sup>4</sup>. In particular, the emergence of Omicron XBB subvariants has dramatically reduced the efficacy of both SARS-CoV-2 wildtype monovalent and bivalent (wildtype + Omicron BA.5) mRNA vaccines<sup>5</sup>, prompting the United States Food and Drug Administration (FDA) to authorize monovalent XBB.1.5-spike-based vaccines for individuals who are older than 6 months, starting in the Fall of 2023 (ref. 6). Preliminary studies indicate that the updated monovalent vaccines substantially boosted serum virus-neutralizing antibody titers against previously dominant Omicron subvariants, such as XBB.1.5 and EG.5.1 (refs. 7-10), but their impact on viral variants that have subsequently emerged remains to be determined.

A number of SARS-CoV-2 Omicron subvariants have emerged recently, with several gaining traction in different parts of the globe<sup>11</sup> (**Figure 1a**). Notably, half of the new infections in Asia are attributed to HK.3, whereas HV.1 constitutes upwards of 20% of the new cases in North America. In Europe, subvariants JD.1.1, BA.2.86, and JN.1 are expanding, each accounting for more than 3% presently. HV.1, HK.3, and JD.1.1 have evolved from the XBB lineage, while JN.1 is a slight variant of BA.2.86 (ref. 2), which emerged independently from Omicron BA.2 (**Figure 1b**). Genetically, these subvariants have accumulated additional mutations in their spike proteins. Compared to the recently dominant EG.5.1, HK.3 possesses a unique mutation, L455F, while HV.1 carries two more mutations, F157L and L452R (**Figure 1c**). JD.1.1 has three spike substitutions on top of those found in XBB.1.5, including the so-called “flip mutations” L455F and F456L as well as A475V. Moreover, JN.1 has an additional L455S mutation on the spike protein of BA.2.86 (**Figure 1d**). Interestingly, the aforementioned mutations reside predominantly in the class-1 epitope cluster<sup>12</sup> on the receptor-binding domain (RBD) of spike (**Extended Data Figure 1**). In this study, we examined the clinical outcome of an XBB.1.5 monovalent mRNA vaccine boost on serum neutralizing antibodies against these emerging and expanding SARS-CoV-2 Omicron subvariants.

## Results

### Serum neutralization of emerging viral subvariants after an XBB.1.5 mRNA booster

To investigate the neutralizing antibody responses induced by XBB.1.5 mRNA monovalent vaccines against currently circulating and newly emerged subvariants, serum samples from 60 individuals across three different cohorts were collected. To accurately represent real-world conditions, all participants had previously received three to four doses of wildtype monovalent mRNA vaccines followed by one dose of a BA.5 bivalent mRNA vaccine. The three cohorts were 1) individuals with no recorded SARS-CoV-2 infections who received an XBB.1.5 monovalent vaccine booster (“XBB.1.5 MV”); 2) individuals with a recent XBB infection who did not receive an XBB.1.5 vaccine booster (“XBB infx”); and 3) individuals with a prior Omicron infection who also received an XBB.1.5 monovalent vaccine booster (“Omicron infx + XBB.1.5 MV”). The final cohort was further divided into two subgroups: subgroup 1 with a documented infection prior

to 2023 (pre-XBB Omicron infection), and subgroup 2 with a documented infection after February 2023 (XBB infection). Detailed demographics of study participants and their vaccination and infection histories are summarized in **Extended Data Tables 1 and 2**. **Figure 2a** depicts the timeline of vaccine administration, SARS-CoV-2 infection, and serum collection for each cohort, and the time intervals between serum samples pre and post XBB.1.5 infection or monovalent vaccine boost are similar.

VSV-pseudotyped viruses were constructed for the emerging subvariants HV.1, HK.3, JD.1.1, and JN.1 as well as D614G, BA.5, XBB.1.5, EG.5.1. These pseudoviruses were then subjected to neutralization assays by pre and post serum samples from the cohorts. In the “XBB.1.5 MV” cohort, the post-vaccination sera showed a 3.2-fold increase in neutralizing ID<sub>50</sub> (50% inhibitory dilution) titers against D614G and a 6.8-fold increase against BA.5, compared to pre-vaccination sera (**Figure 2b**). A larger increase in ID<sub>50</sub> titers was observed between pre and post sera against XBB.1.5, EG.5.1, HV.1, HK.3, JD.1.1, and JN.1, ranging from 13.3 to 27.6-fold. The magnitude of these boosts was similar to those found for the “XBB infx” cohort (**Figure 2c**), which exhibited a 3.0-fold increase against D614G, a 7.1-fold increase against BA.5, and 13.4-to-28.6-fold increases against XBB.1.5 and subsequent Omicron subvariants. Not surprisingly, sera from the “Omicron infx + XBB.1.5 MV” cohort displayed highest neutralization titers overall but smaller increases (**Figure 2d**), largely attributable to higher titers in pre-vaccination samples due to a prior Omicron infection. Notably, the increase in neutralization activity following the XBB.1.5 monovalent vaccine booster was again much more pronounced against XBB.1.5 and newer Omicron subvariants (7.5-to-10.6-fold), compared to D614G and BA.5 (2.7-fold and 3.9-fold, respectively). No obvious differences in neutralizing titers were observed between subgroups 1 and 2 in the last cohort (**Figure 2d**).

After XBB.1.5 vaccination or infection across all three cohorts, the serum neutralization ID<sub>50</sub> titers against D614G were the highest, ranging from 6,088 to 22,978, followed by those against BA.5, ranging from 3,121 to 15,948 (**Figures 2b, 2c, and 2d**). Compared to BA.5, XBB.1.5 was significantly more (3.1-to-5.6-fold) resistant to neutralization by these sera, whereas it was minimally or marginally more (1.0-to-2.2-fold) sensitive than EG.5.1. Serum neutralization titers against newly emerged subvariants HV.1, HK.3, and JD.1.1 were quite similar, but significantly lower than that against XBB.1.5 by 1.6-to-2.5-fold. Overall, serum titers against JN.1 were the lowest, by 2.9-to-4.3-fold relative to titers against XBB.1.5, which is expected given the exposure histories of these cohorts. Importantly, the absolute neutralization titers were robust against all viral variants tested for serum samples after XBB.1.5 vaccination or infection (**Figures 2b, 2c, and 2d**), and the potency and breadth of the antibody boosts were similar for the two XBB.1.5 monovalent mRNA vaccines from different manufacturers, Moderna and Pfizer (**Extended Data Figures 2a and 2b**).

### Antigenic cartography

The serum neutralization data from all three cohorts combined, as well as individually, were used to construct antigenic maps (**Figures 3a-3d**), which graphically emphasize several key points. First, the discernible shortening of antigenic distances between D614G and other SARS-CoV-2 variants after a shot of XBB.1.5 monovalent vaccine (**Figures 3b and 3d**) was indicative of the significant boost in antibody potency and breadth. Second, the shortening of these antigenic

distances after XBB.1.5 infection was also similar (**Figure 3c**) to that of XBB.1.5 vaccine booster (**Figure 3b**), suggesting that infection and vaccination resulted in comparable enhancement of antibody responses. Third, the emergent subvariants HV.1, HK.3, and JD.1.1 clustered together but were more distant than XBB.1.5 and EG.5.1 (**Figure 3**), demonstrating not only their antigenic similarity but also their greater antibody resistance compared to their predecessors. Lastly, JN.1 was antigenically distinct and more distant.

### Comparison of XBB.1.5 monovalent mRNA booster versus BA.5 bivalent mRNA booster

Following the XBB.1.5 monovalent vaccine booster, the highest neutralizing titers were observed against D614G and BA.5, not against XBB.1.5 (**Figures 2b and 2d**). This finding showed that there was considerable “back boosting” of antibodies directed to prior SARS-CoV-2 variants, which is likely the consequence of immunological imprinting<sup>13</sup> from prior vaccinations with the wildtype monovalent vaccine and the BA.5 bivalent vaccine. Nevertheless, an XBB.1.5 monovalent vaccine booster did markedly elevate serum neutralization titers against all Omicron subvariants tested (**Figures 2b and 2d**), in contrast to prior results obtained after the BA.5 bivalent vaccine boost<sup>14-18</sup>. We therefore compared the severity of immunological imprinting between XBB.1.5 monovalent vaccine and BA.5 bivalent vaccine. Serum neutralization data against D614G, BA.5, and XBB.1.5, generated using assays identical to those described herein, were extracted from our previous report<sup>17</sup> on a cohort of individuals who received four shots of a wildtype monovalent vaccine followed by two shots of a BA.5 bivalent vaccine, and then compared with data extracted from two cohorts in the present study (**Figure 4a**). In individuals who received a second BA.5 bivalent booster, increases in mean serum neutralization titers against BA.5 were similar to that against D614G (2.6-fold versus 2.0-fold) (**Figure 4b**). However, strikingly, both the XBB.1.5 monovalent vaccine booster cohort (**Figure 4c**) and XBB breakthrough infection cohort (**Figure 4d**) showed markedly higher increases in mean neutralizing antibody titers against XBB.1.5 (27.0-fold and 28.6-fold, respectively) than against D614G (3.2-fold and 3.0-fold, respectively). These contrasting findings indicate that immunological imprinting is less severe for the XBB.1.5 monovalent vaccines.

### Discussion

Our findings showed that both XBB.1.5 monovalent mRNA vaccine booster or XBB.1.5 breakthrough infection markedly increased the magnitude of serum neutralizing antibodies against currently prevalent SARS-CoV-2 Omicron subvariants such as XBB.1.5 and EG.5.1 (**Figure 2**), in general agreement with clinical data posted by Chalkias et al<sup>7</sup> and Stankov et al<sup>8</sup>, and animal immunization results posted by Patel et al<sup>9</sup>, and Modjarrad et al<sup>10</sup>. The latter three studies also found that there are strong specific T-cell responses directed to the spike protein of XBB subvariants<sup>8-10</sup>. Here, we extended our study to include emerging Omicron subvariants that are now gaining traction and expanding rapidly, including HV.1, HK.3, JD.1.1, which are descendants of the XBB lineage, as well as JN.1, which is closely related to BA.2.86 (**Figure 1**). Serum neutralizing titers against these emergent viruses increased by ~13-to-27-fold after an XBB.15 monovalent vaccine booster in individuals without an infection history (**Figure 2b**), and by ~10-fold in individuals with a prior Omicron infection (**Figure 2d**). Interestingly, we also showed that those boosted by an XBB.1.5 monovalent vaccine elicited serum neutralization potency and breadth similar to those with an XBB.1.5 breakthrough infection (**Figures 2b & 2c and 3b & 3c**).

Our results also showed that HV.1, HK.3, and JD.1.1 are more resistant to serum neutralization than XBB.1.5 by about 1.6-to-2.5-fold (**Figures 2b-2d**), a finding that suggests that these emergent subvariants are likely to have a growth advantage in the population over their immediate precursors. If so, we can expect these new sublineages to replace XBB.1.5 and EG.5.1. Likewise, JN.1 is even more antibody resistant, by 2.9-to-4.3-fold, to the serum samples tested here (**Figure 3**). Widespread application of the updated XBB.1.5 monovalent vaccines could confer an even larger growth advantage in the population to JN.1 as well as to the related BA.2.86, thereby posing a potential threat to the newly authorized COVID-19 vaccines.

While immunological imprinting is evident with the XBB.1.5 monovalent mRNA vaccines studied, as discussed above, it is not nearly as severe as those observed for the BA.5 bivalent vaccines (**Figure 4**). One potential explanation is that XBB.1.5 is genetically and antigenically more distant from the ancestral SARS-CoV-2 than BA.5, which might mitigate immunological imprinting to an extent. Perhaps a more likely explanation is the non-inclusion of the ancestral spike in the current XBB.1.5 monovalent vaccines. Previous studies on the bivalent WA1+BA5 vaccines by our team<sup>14-17</sup> and others<sup>18</sup> suggested that the inclusion of the ancestral spike exacerbated the problem of imprinting and recommended its removal. Our findings herein indicate that WHO, FDA, and the vaccine manufacturers made the right choice by formulating the new COVID-19 vaccines based on XBB.1.5 spike alone, without including the ancestral spike.

This study is limited to evaluation of serum neutralizing antibodies, without addressing T-cell responses<sup>19-21</sup> or mucosal immunity<sup>22-24</sup>, both of which could provide added protection against SARS-CoV-2. Moreover, we have only examined acute antibody responses after XBB.1.5 monovalent vaccine booster or XBB.1.5 infection, but how such responses evolve over time will require follow-up studies. These limitations notwithstanding, our results not only demonstrate that administration of an XBB.1.5 monovalent mRNA vaccine booster can elicit robust neutralizing antibodies against current and emerging SARS-CoV-2 variants, but also support FDA's recommendation to apply these updated COVID-19 vaccines more widely to confer greater protection to the public.

## Materials and Methods

### Clinical cohorts

Longitudinal sera were obtained as part of a continuing cohort study, Immunity-Associated with SARS-CoV-2 Study (IASO), which began in 2020 at the University of Michigan in Ann Arbor, Michigan<sup>25</sup>. Written informed consent was provided by all participants and sera were collected according to the protocol approved by the Institutional Review Board of the University of Michigan Medical School. Participants in the IASO study completed weekly symptom surveys and were tested for SARS-CoV-2 with any report of symptoms. All serum samples were examined by anti-nucleoprotein (NP) ELISA to confirm status of prior SARS-CoV-2 infection.

For this study, we included sera from 60 individuals in three distinct clinical cohorts: 1) individuals with no recorded SARS-CoV-2 infections who had received an XBB.1.5 monovalent vaccine booster (“XBB.1.5 MV”); 2) individuals with a recent XBB SARS-CoV-2 infection who had not received the XBB.1.5 booster (“XBB infx”); and 3) individuals with prior infection who also received the XBB.1.5 booster (“Omicron infx + XBB.1.5 MV”). The final cohort was divided into subgroup 1, with documented infection prior to 2023, and subgroup 2, with documented infection after February 2023. Individuals in all cohorts received either three or four doses of a wildtype monovalent vaccine as well as a single BA.5 bivalent booster.

Most participants were female (78.3%) with an average age of 49.7 years. Sera were collected an average of 26 days pre and post XBB.1.5 vaccination or XBB infection. Sera were examined by anti-nucleoprotein (NP) ELISA to determine status of prior SARS-CoV-2 infection. Demographic, vaccination, and serum collection details are summarized for each cohort and subgroup in **Extended Data Table 1**, and details are shown for each participant in **Extended Data Table 2**.

### Cell lines

293T (CRL-3216) and Vero-E6 (CRL-1586) cells were obtained from ATCC and cultured in the conditions following manufacturer’s instructions. The morphology of each cell line was visually confirmed before use. All cell lines tested negative for mycoplasma.

### Neutralization assay

Plasmids encoding SARS-CoV-2 variant spikes, including D614G, BA.5, XBB.1.5, and EG.5.1, were generated in previous studies<sup>3,5,16,26</sup>. Plasmids expressing HV.1, HK.3, JD.1.1, and JN.1 spikes were generated by introducing mutations to the XBB.1.5 (ref. 16), EG.5.1 (ref. 3) or BA.2.86 (ref. 2) spike (**Figure 1C**) using the QuikChange® mutagenesis kit.

To produce pseudotyped viruses of SARS-CoV-2 variants, 293T cells were transfected with the spike-encoding plasmids described above using 1 mg/mL PEI (Polyethylenimine). One day post-

transfection, the 293T cells were then incubated with VSVG\* $\Delta$ G-luciferase (Kerafast, Inc.) at a multiplicity of approximately 3 to 5 for 2 hours followed by three washes with PBS. The cells were then cultured with fresh medium for an additional day. Cell supernatants containing viruses were collected, clarified by centrifugation, aliquoted, and stored at  $-80^{\circ}\text{C}$  until use.

The viral titer of each variant was titrated and normalized for the neutralization assays. Serum samples were diluted in triplicate in 96-well plates, starting from a 12.5-fold dilution, and then incubated with an equal volume of virus for 1 hour at  $37^{\circ}\text{C}$  before adding  $2 \times 10^4$  cells/well of Vero-E6 cells. The cells were then cultured overnight, harvested, and lysed for measurement of luciferase activity using SoftMax Pro v.7.0.2 (Molecular Devices). Reductions in luciferase activity at given dilutions of sera were calculated, and  $\text{ID}_{50}$  values of sera were obtained by fitting the virus-reduction data using a non-linear five-parameter dose-response curve in GraphPad Prism V.10.

### **Phylogenetic analysis**

Genome sequences of SARS-CoV-2 subvariants are retrieved from the GISAID database<sup>11</sup>. The spike protein sequences are then extracted from these genomes using an in-house Python script. Post-extraction, these sequences are aligned by MUSCLE software, version 3.8.31. Sequencing sites with low quality, identified by the presence of 'N', underwent a manual curation to align the mutations with the consensus for each variant. A Maximum-Likelihood phylogenetic tree was constructed with MEGA11 software, utilizing the Tamura-Nei model, and its robustness was verified through 500 bootstrap replications.

### **Antigenic cartography**

The antigenic distances between serum samples and D614G, along with other SARS-CoV-2 variants, were calculated by integrating the  $\text{ID}_{50}$  values of individual serum samples using a published antigenic cartography method<sup>27</sup>. Visualizations are created with the Racmacs package (version 1.1.4, <https://acorg.github.io/Racmacs/>) within R software version 4.0.3. The optimization is set to 2,000 steps, with the “minimum column basis” parameter set to “none”. The “mapDistances” function was used to calculate the antigenic distances, with the average distances from all serum samples to each variant representing the final outputs. For each group, D614G was positioned as the center point of the sera. The seeds for each antigenic map are manually adjusted to position D614G left horizontally in relation to other variants.

## **Acknowledgements**

This study was supported by funding from the NIH SARS-CoV-2 Assessment of Viral Evolution (SAVE) Program (Subcontract No. 0258-A709-4609 under Federal Contract No. 75N93021C00014) to D.D.H., as well as funding from the NIH contract 75N93019C00051 to A.G. We express our gratitude to Zijin Chu, Theresa Knowalski-Dobson, Emily Stoneman, David Manthei, Anna Buswinka, Gabe Simjanovski, Joseph Wendzinski, Mayurika Patel, Kathleen Lindsey, Dawson Davis, Victoria Blanc, Savanna Sneeringer, and Pamela Bennett-Baker of the IASO study team for conducting the IASO study.

## **Author Contributions**


The study was conceptualized by A.G., L.L. and D.D.H. Experiments were conducted and data analyzed by Q.W., L.L., Y.G., I.A.M., and A.B. Project management was handled by Q.W. Serum samples were collected by R.V., C.G., A.G., and their colleagues. The results were analyzed and the manuscript was written by Q.W., Y.G., L.L., and D.D.H. All contributing authors have reviewed and endorsed the manuscript.

## **Declaration of Interests**

D.D.H. co-founded TaiMed Biologics and RenBio, and he serves as a consultant for WuXi Biologics and Brie Biosciences and is a board director at Vicarious Surgical. A.G. served as a member of the scientific advisory board for Janssen Pharmaceuticals. The remaining authors declare no conflicts of interest.









**Figure 2. Neutralizing antibody titers before and after an XBB.1.5 mRNA booster, XBB infection, or both.**

- a.** Timeline representation of vaccine administration, SARS-CoV-2 infection, and serum collection intervals for each clinical cohort. Indicated timepoints represent the median in days for each cohort, with day 0 defined as the day of the initial SARS-CoV-2 vaccination. Numbers of participants for each group receiving a fourth wildtype (WT) monovalent vaccine (MV) is indicated. Other vaccine doses were received by all participants in each cohort. 15 participants from the “Omicron infx + XBB.1.5 MV” cohort had a pre-XBB Omicron infection (subgroup 1), while the other 10 had XBB infection (subgroup 2). n, sample size.
- b.** Serum virus-neutralizing titers ( $ID_{50}$ ) of the cohorts against the indicated SARS-CoV-2 pseudoviruses. Geometric mean  $ID_{50}$  titers (GMT) are shown along with the fold-change between pre and post (MV or infx) serum samples. Horizontal bars show the fold change in GMT following XBB MV or infection between XBB.1.5 and all other viruses tested. The dotted line represents the assay limit of detection (LOD) of 25. Numbers under the dotted lines are non-responders to XBB MV or infection (<3-fold increase in  $ID_{50}$  titers between pre- and post-XBB sera across all the viruses tested). In the “Omicron infx + XBB.1.5 MV” cohort, subgroups 1 and 2 are shown in rhombuses and circles, respectively. Statistical analyses were performed by Wilcoxon matched-pairs signed-rank tests.



**Figure 3. Antigenic cartography of serum virus-neutralizing data.**

Antigenic maps for all cohorts (a), the XBB.1.5 monovalent vaccine (XBB.1.5 MV) cohort (b), the XBB infection (XBB infx) cohort (c), and the infection + XBB.1.5 monovalent vaccine (Omicron infx + XBB.1.5 MV) cohort (d). The top row shows antigenic maps generated with pre-XBB sera, and the bottom row shows maps generated with post-XBB sera. The length of each square in the antigenic maps corresponds to one antigenic unit and represents an approximately 2-fold change in ID<sub>50</sub> titer. Virus positions are shown in closed circles, while serum positions are shown by gray squares (pre-XBB sera) or pink squares (post-XBB sera). Antigenic distance from D614G is shown for each virus in parenthesis.



**Figure 4. XBB.1.5 monovalent mRNA vaccines induced stronger boosts than a second BA.5 bivalent mRNA vaccine.**


- a.** Timeline representation of vaccine administration, SARS-CoV-2 infection, and serum collection intervals for each cohort. The cohort that received a second BA.5 bivalent vaccine (BA.5 BV x2) was previously described<sup>17</sup>. Indicated timepoints represent the median in days for each cohort, with day 0 defined as the day of the initial SARS-CoV-2 vaccination. Numbers of participants for each group receiving a fourth wildtype (WT) monovalent vaccine is indicated. n, sample size.
- b-d.** Fold changes in ID<sub>50</sub> titers of the indicated cohorts against D614G, BA.5, and XBB.1.5 between pre and post vaccination or infection. Geometric mean fold changes in ID<sub>50</sub> titer are shown as black bars and denoted above the dots. Statistical analyses were performed by employing Wilcoxon matched-pairs signed-rank tests. Data for the BA.5 BV x2 cohort were extracted from a previously published study<sup>17</sup>.

**Extended Data Table 1. Summarized participant information.** Demographics, vaccines, and serum collection information are summarized for each cohort. Listed values represent the mean and range (age and sera collection variables) or number and percentage (vaccine type and sex variables).

Clinical information	All participants		XBB.1.5 MV		XBB infx		Prior Infx + XBB MV				
	No. or Mean	% or (range)	No. or Mean	% or (range)	No. or Mean	% or (range)	Pre-XBB infx + XBB.1.5 MV		XBB infx + XBB.1.5 MV		
							No. or Mean	% or (range)	No. or Mean	% or (range)	
<b>Total case</b>	60	-	16	-	19	-	15	-	10	-	
<b>Female</b>	47	78.3%	11	68.8%	16	84.2%	12	80.0%	8	80.0%	
<b>Male</b>	13	21.7%	5	31.3%	3	15.8%	3	20.0%	2	20.0%	
<b>Age</b>	49.7	(30,77)	51.8	(36,65)	48.6	(33,77)	47.8	(35,67)	51.1	(30,62)	
<b>WT monovalent Dose 1 and 2</b>	Pfizer	53	88.3%	14	87.5%	17	89.5%	14	93.3%	8	80.0%
	Moderna	6	10.0%	2	12.5%	2	10.5%	1	6.7%	1	10.0%
	Janssen	1	1.7%	-	-	-	-	-	-	1	10.0%
<b>WT monovalent Dose 3</b>	Pfizer	51	85.0%	14	87.5%	16	84.2%	14	93.3%	7	70.0%
	Moderna	9	15.0%	2	12.5%	3	15.8%	1	6.7%	3	30.0%
<b>WT monovalent Dose 4</b>	Pfizer	18	30.0%	5	31.3%	6	31.6%	3	20.0%	4	40.0%
	Moderna	8	13.3%	4	25.0%	2	10.5%	-	-	2	20.0%
	None	34	56.7%	7	43.8%	11	57.9%	12	80.0%	4	40.0%
<b>BA.5 bivalent booster</b>	Pfizer	38	63.3%	9	56.3%	16	84.2%	8	53.3%	5	50.0%
	Moderna	22	36.7%	7	43.8%	3	15.8%	7	46.7%	5	50.0%
<b>XBB.1.5 monovalent booster</b>	Pfizer	20	33.3%	8	50.0%	-	-	7	46.7%	5	50.0%
	Moderna	21	35.0%	8	50.0%	-	-	8	53.3%	5	50.0%
	None	19	31.7%	-	-	19	100.0%	-	-	-	-
<b>Sera Days Pre XBB</b>		26.5	(1,74)	19.8	(1,74)	30.8	(3,69)	28.1	(2,69)	26.8	(7,55)
<b>Sera Days Post XBB</b>		26.4	(20,34)	26.0	(21,32)	27.8	(22,30)	25.9	(20,34)	24.9	(21,30)

## Extended Data Table 2. Participant details. Details are listed for each participant including demographics as well as vaccine, infection, and serum collection information.

Sample ID	Age	Gender	Infection period	Vaccine type						Days pre/post vaccine/infection				Intervals between 1 <sup>st</sup> dose to			
				WT monovalent vaccine				BA.5 bivalent booster	XBB.1.5 Monovalent booster	pre sample	post sample	2 <sup>nd</sup> dose	3 <sup>rd</sup> dose	4 <sup>th</sup> dose	BA.5 bivalent booster	Omicron infection	XBB.1.5 Monovalent booster
				dose 1	dose 2	dose 3	dose 4										
<b>XBB.1.5 MV (n=16)</b>																	
1	62	Female	-	Pfizer	Pfizer	Pfizer	Pfizer	Pfizer	Moderna	21	27	22	268	491	657	-	993
2	59	Male	-	Pfizer	Pfizer	Pfizer	Pfizer	Pfizer	Pfizer	6	23	21	269	491	622	-	1001
3	65	Female	-	Pfizer	Pfizer	Pfizer	Pfizer	Pfizer	Pfizer	24	28	22	266	503	637	-	990
4	59	Female	-	Pfizer	Pfizer	Pfizer	-	Pfizer	Pfizer	9	28	21	289	-	624	-	992
5	55	Female	-	Pfizer	Pfizer	Pfizer	Moderna	Moderna	Moderna	32	25	21	272	472	637	-	995
6	38	Male	-	Moderna	Moderna	Moderna	-	Moderna	Pfizer	22	27	28	235	-	539	-	914
7	64	Female	-	Pfizer	Pfizer	Pfizer	Pfizer	Pfizer	Pfizer	16	32	21	270	455	606	-	976
8	55	Female	-	Pfizer	Pfizer	Pfizer	Moderna	Moderna	Moderna	23	26	21	291	487	648	-	1005
9	56	Female	-	Pfizer	Pfizer	Pfizer	-	Pfizer	Pfizer	26	21	21	377	-	634	-	993
10	40	Male	-	Pfizer	Pfizer	Pfizer	-	Moderna	Moderna	3	22	21	268	-	584	-	969
11	50	Male	-	Pfizer	Pfizer	Pfizer	Moderna	Pfizer	Moderna	8	31	21	235	444	621	-	996
12	54	Female	-	Pfizer	Pfizer	Pfizer	Moderna	Pfizer	Moderna	1	22	21	329	490	623	-	990
13	38	Female	-	Pfizer	Pfizer	Pfizer	-	Moderna	Pfizer	74	30	21	276	-	619	-	985
14	56	Female	-	Pfizer	Pfizer	Pfizer	Pfizer	Moderna	Moderna	10	22	21	287	507	654	-	1016
15	36	Male	-	Moderna	Moderna	Moderna	-	Moderna	Moderna	26	26	27	232	-	526	-	905
16	42	Female	-	Pfizer	Pfizer	Pfizer	-	Moderna	Pfizer	16	26	21	239	-	520	-	910
<b>XBB infx (n=19)</b>																	
1	33	Female	2023.02	Pfizer	Pfizer	Pfizer	-	Pfizer	-	5	30	21	334	-	643	151	-
2	38	Female	2023.08	Pfizer	Pfizer	Pfizer	-	Pfizer	-	53	27	24	294	-	666	307	-
3	59	Female	2023.08	Pfizer	Pfizer	Pfizer	Pfizer	Pfizer	-	37	26	21	295	472	660	280	-
4	44	Male	2023.05	Pfizer	Pfizer	Pfizer	Pfizer	Moderna	-	69	30	21	243	447	621	280	-
5	54	Female	2023.09	Pfizer	Pfizer	Pfizer	Pfizer	Pfizer	-	37	28	21	222	421	602	306	-
6	77	Male	2023.09	Pfizer	Pfizer	Pfizer	Pfizer	Pfizer	-	48	22	21	289	470	615	365	-
7	38	Female	2023.03	Pfizer	Pfizer	Moderna	Pfizer	Pfizer	-	14	28	21	278	-	613	99	-
8	59	Female	2023.05	Pfizer	Pfizer	Pfizer	Pfizer	-	-	24	30	25	281	469	613	249	-
9	41	Female	2023.02	Pfizer	Pfizer	Pfizer	-	Pfizer	-	24	29	21	289	-	659	108	-
10	38	Female	2023.08	Pfizer	Pfizer	Pfizer	-	Pfizer	-	3	30	21	291	-	660	305	-
11	42	Male	2023.04	Pfizer	Pfizer	Pfizer	-	Moderna	-	24	28	21	269	-	615	229	-
12	38	Female	2023.08	Pfizer	Pfizer	Pfizer	-	Pfizer	-	16	24	21	304	-	644	325	-
13	56	Female	2023.09	Pfizer	Pfizer	Pfizer	Pfizer	Pfizer	-	54	29	21	290	492	645	342	-
14	53	Female	2023.02	Pfizer	Pfizer	Pfizer	-	Pfizer	-	16	27	22	320	-	645	140	-
15	40	Female	2023.05	Pfizer	Pfizer	Pfizer	-	Pfizer	-	21	28	21	279	-	658	194	-
16	49	Female	2023.07	Pfizer	Pfizer	Pfizer	-	Moderna	-	63	30	22	328	-	641	264	-
17	59	Female	2023.04	Moderna	Moderna	Moderna	Moderna	Moderna	-	25	24	28	268	505	584	174	-
18	51	Female	2023.05	Moderna	Moderna	Moderna	Moderna	Moderna	-	39	29	28	253	441	554	228	-
19	54	Female	2023.08	Pfizer	Pfizer	Pfizer	-	Pfizer	-	13	29	23	284	-	632	330	-
<b>Omicron infx + XBB.1.5 MV (n=25)</b>																	
<b>subgroup 1: pre-XBB Omicron infx + XBB.1.5 MV (n=15)</b>																	
1	41	Female	2022.09	Moderna	Moderna	-	Pfizer	Moderna	Moderna	57	25	28	330	-	715	624	1009
2	61	Female	2022.04	Pfizer	Pfizer	Pfizer	-	Moderna	Moderna	22	34	22	302	-	649	487	1006
3	53	Female	2022.04	Pfizer	Pfizer	Pfizer	-	Pfizer	Moderna	35	25	21	275	-	626	471	999
4	49	Male	2022.01	Pfizer	Pfizer	Pfizer	-	Pfizer	Pfizer	12	22	21	265	-	691	320	956
5	67	Female	2022.07	Pfizer	Pfizer	Pfizer	Pfizer	Moderna	Moderna	42	29	21	271	473	690	569	992
6	52	Female	2022.04	Pfizer	Pfizer	Pfizer	Pfizer	Pfizer	Pfizer	27	25	21	266	436	599	460	973
7	48	Female	2022.01	Pfizer	Pfizer	Pfizer	-	Moderna	Pfizer	47	22	21	254	-	554	291	925
8	43	Male	2022.01	Pfizer	Pfizer	Pfizer	-	Pfizer	Pfizer	29	20	21	265	-	614	359	977
9	53	Female	2022.10	Pfizer	Pfizer	Pfizer	-	Pfizer	Pfizer	21	25	21	279	-	760	638	997
10	40	Female	2022.04	Pfizer	Pfizer	Pfizer	-	Moderna	Moderna	69	21	24	276	-	638	467	1003
11	37	Female	2022.05	Pfizer	Pfizer	Pfizer	-	Moderna	Moderna	8	20	21	280	-	643	508	1009
12	43	Female	2022.01	Pfizer	Pfizer	Pfizer	-	Moderna	Pfizer	3	32	21	234	-	566	309	913
13	36	Male	2022.08	Pfizer	Pfizer	Pfizer	-	Moderna	Moderna	2	30	21	316	-	655	583	980
14	59	Female	2022.04	Pfizer	Pfizer	Pfizer	Pfizer	Pfizer	Moderna	6	29	21	277	543	610	448	986
15	35	Female	2022.06	Pfizer	Pfizer	Pfizer	Pfizer	Pfizer	Pfizer	42	29	22	277	-	651	527	1008
<b>subgroup 2: XBB infx + XBB.1.5 MV (n=10)</b>																	
1	54	Female	2023.02	Pfizer	Pfizer	Pfizer	Moderna	Pfizer	Moderna	21	22	21	262	492	632	774	1003
2	62	Female	2023.04	Pfizer	Pfizer	Pfizer	Pfizer	Pfizer	Moderna	40	29	21	294	516	630	845	1000
3	61	Female	2023.04	Pfizer	Pfizer	Pfizer	Pfizer	Moderna	Moderna	53	26	21	275	519	625	843	1004
4	30	Female	2023.08	Pfizer	Pfizer	Pfizer	-	Moderna	Pfizer	21	22	21	218	-	580	922	880
5	58	Female	2023.02	Pfizer	Pfizer	Pfizer	-	Pfizer	Pfizer	10	22	21	284	-	682	1000	776
6	61	Male	2023.05	Pfizer	Pfizer	Moderna	-	Moderna	Moderna	7	30	21	231	-	541	917	800
7	42	Female	2023.03	Pfizer	Pfizer	Pfizer	Pfizer	Moderna	Pfizer	13	29	21	266	477	608	800	996
8	62	Female	2023.06	Pfizer	Pfizer	Pfizer	Pfizer	Pfizer	Pfizer	18	21	21	277	439	643	895	1002
9	46	Male	2023.05	J&J-Janssen	J&J-Janssen	Moderna	-	Pfizer	Pfizer	55	24	214	386	-	543	776	921
10	35	Female	2023.06	Moderna	Moderna	Moderna	Moderna	Moderna	Moderna	30	24	28	342	437	616	892	1014




**Extended Data Figure 1. Spike mutations found in emerging SARS-CoV-2 Omicron subvariants.**

**a.** Mutations found in EG.5.1, HV.1, HK.3, JD.1.1, and GK.3 on top of the XBB.1.5 spike.

**b.** Location of the L455S mutation in JN.1 on top of the BA.2.86 spike.

Mutations present in XBB.1.5 and BA.2.86 are highlighted in cyan. The spike protein structure is obtained under PDB ID: 6ZGE<sup>28</sup>.



**Extended Data Figure 2. Neutralizing antibody titers before and after a Moderna or Pfizer XBB.1.5 mRNA vaccine booster.** Participants from the “XBB.1.5 MV” cohort (a) and “Omicron infx + XBB.1.5 MV” (b) were stratified into two groups based on the vaccine manufacturer. Geometric mean ID<sub>50</sub> titers are shown along with the fold change between pre and post XBB.1.5 vaccination against each indicated virus. The dotted line represents the assay limit of detection of 25. “n” denotes the sample size.



## References:

- 1 WHO. *Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic*, <[https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-\(2005\)-emergency-committee-regarding-the-coronavirus-disease-\(covid-19\)-pandemic](https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic)> (2023).
- 2 Wang, Q. *et al.* Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike. *Nature*, doi:10.1038/s41586-023-06750-w (2023).
- 3 Wang, Q. *et al.* Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6. *Lancet Infect Dis* **23**, e397-e398, doi:10.1016/S1473-3099(23)00555-8 (2023).
- 4 Carabelli, A. M. *et al.* SARS-CoV-2 variant biology: immune escape, transmission and fitness. *Nat Rev Microbiol* **21**, 162-177, doi:10.1038/s41579-022-00841-7 (2023).
- 5 Wang, Q. *et al.* Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. *Cell* **186**, 279-286 e278, doi:10.1016/j.cell.2022.12.018 (2023).
- 6 FDA. *Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2023*, <<https://www.fda.gov/vaccines-blood-biologics/updated-covid-19-vaccines-use-united-states-beginning-fall-2023>> (2023).
- 7 Chalkias, S. *et al.* Safety and Immunogenicity of XBB.1.5-Containing mRNA Vaccines. *medRxiv*, 2023.2008.2022.23293434, doi:10.1101/2023.08.22.23293434 (2023).
- 8 Stankov, M. V. *et al.* Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination. *medRxiv*, 2023.2010.2004.23296545, doi:10.1101/2023.10.04.23296545 (2023).
- 9 Patel, N. *et al.* XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants. *Sci Rep* **13**, 19176, doi:10.1038/s41598-023-46025-y (2023).
- 10 Modjarrad, K. *et al.* Preclinical Characterization of the Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine. *bioRxiv*, 2023.2011.2017.567633, doi:10.1101/2023.11.17.567633 (2023).
- 11 Elbe, S. & Buckland-Merrett, G. Data, disease and diplomacy: GISAID's innovative contribution to global health. *Glob Chall* **1**, 33-46, doi:10.1002/gch2.1018 (2017).
- 12 Barnes, C. O. *et al.* SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. *Nature* **588**, 682-687, doi:10.1038/s41586-020-2852-1 (2020).
- 13 Koutsakos, M. & Ellebedy, A. H. Immunological imprinting: Understanding COVID-19. *Immunity* **56**, 909-913, doi:10.1016/j.immuni.2023.04.012 (2023).
- 14 Wang, Q. *et al.* Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine. *Cell Rep Med*, 101258, doi:10.1016/j.xcrm.2023.101258 (2023).
- 15 Wang, Q. *et al.* Antibody Response to Omicron BA.4-BA.5 Bivalent Booster. *N Engl J Med* **388**, 567-569, doi:10.1056/NEJMc2213907 (2023).
- 16 Wang, Q. *et al.* SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster. *Lancet Infect Dis* **23**, 527-528, doi:10.1016/S1473-3099(23)00181-0 (2023).
- 17 Wang, Q. *et al.* SARS-CoV-2 neutralising antibodies after a second BA.5 bivalent booster. *Lancet* **402**, 1827-1828, doi:10.1016/S0140-6736(23)02278-X (2023).
- 18 Collier, A. Y. *et al.* Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters. *N Engl J Med* **388**, 565-567, doi:10.1056/NEJMc2213948 (2023).
- 19 Sette, A. & Crotty, S. Adaptive immunity to SARS-CoV-2 and COVID-19. *Cell* **184**, 861-880, doi:10.1016/j.cell.2021.01.007 (2021).
- 20 Zhang, Z. *et al.* Humoral and cellular immune memory to four COVID-19 vaccines. *Cell* **185**, 2434-2451 e2417, doi:10.1016/j.cell.2022.05.022 (2022).
- 21 Vogel, A. B. *et al.* BNT162b vaccines protect rhesus macaques from SARS-CoV-2. *Nature* **592**, 283-289, doi:10.1038/s41586-021-03275-y (2021).
- 22 Tang, J. *et al.* Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination. *Sci Immunol* **7**, eadd4853, doi:10.1126/sciimmunol.add4853 (2022).

- 23 Afkhami, S. *et al.* Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. *Cell* **185**, 896-915 e819, doi:10.1016/j.cell.2022.02.005 (2022).
- 24 Mao, T. *et al.* Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses. *Science* **378**, eabo2523, doi:10.1126/science.abo2523 (2022).
- 25 Simon, V. *et al.* PARIS and SPARTA: Finding the Achilles' Heel of SARS-CoV-2. *mSphere* **7**, e0017922, doi:10.1128/msphere.00179-22 (2022).
- 26 Wang, Q. *et al.* Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. *Nature* **608**, 603-608, doi:10.1038/s41586-022-05053-w (2022).
- 27 Smith, D. J. *et al.* Mapping the antigenic and genetic evolution of influenza virus. *Science* **305**, 371-376, doi:10.1126/science.1097211 (2004).
- 28 Wrobel, A. G. *et al.* SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects. *Nat Struct Mol Biol* **27**, 763-767, doi:10.1038/s41594-020-0468-7 (2020).